Notably, the frequency of ALK fusions in patients with adenocarcinomas that did not exhibit EGFR/KRAS mutations reached 45.0% (9/21), strongly indicating that only a specific molecular subset of adenocarcinomas is characterized by EML4-ALK fusion. This evidence concerns the gene KRAS and adenocarcinoma.